We were excited for the opportunity to see our colleagues in person at #ICPE2022! Here's a look at the schedule of research and other opportunities we presented. Reach out to us - we'd love to chat.
Our study evaluated whether the use of antidepressants with anticholinergic properties were associated with dementia, as prior studies showed. We estimated the per-protocol effect of adhering to 3 different treatment strategies on the 12-year risk of dementia. The first two strategies involved the initiation of antidepressants either with or without anticholinergic properties for at least 4 months. The third strategy involved no initiation of antidepressants.
Our target trial emulation design differed from previous studies in several ways.
Our results showed both an increase of 1.6% and a decrease of approximately 2% in the risk of dementia after 12 years of follow-up when comparing initiators of antidepressants with anticholinergic properties with initiators of antidepressants without anticholinergic properties. Long-term exposure to antidepressants, regardless of their anticholinergic properties, slightly increased the risk of dementia.
See research abstract here.
As part of a postauthorisation safety study, we evaluated cardiovascular safety endpoints related to the use of aclidinium.
The study evaluated the risk of acute myocardial infarction, stroke, and other major adverse cardiac events in new users of aclidinium, aclidinium/formoterol, and other inhaled COPD medications compared with new users of long-acting beta agonists. This cohort study included patients with COPD aged 40 years or older initiating the study medications in the UK Clinical Practice Research Datalink between 2012 and 2019. Results showed that current use of aclidinium and other study medications was not associated with a clinically meaningful risk of any of the study outcomes.
See research abstract here.
In this work on perinatal epidemiology, our aim was to provide estimates of gestational age at birth that could inform assumptions when clinical estimates of gestational age at birth are not available. For this, we reviewed birth certificates from the US in 2019 and 2020. We found that the median and mode gestational age at birth were 39 weeks overall. This was also true in most groups of singletons, regardless of maternal age, smoking in pregnancy, or maternal body mass index.
Gestational age at birth was lower in some groups, and less narrowly defined. These groups were generally defined by pregnancy or neonatal complications or by multifetal pregnancies, such as twins or triplets.
The results of this research provide information that other researchers can use to estimate the duration of pregnancy in database studies when clinical or obstetrical information is lacking.
See research abstract here.
See who from RTI-HS will be attending in person. Reach out if you would like to set up a meeting with one of our team members in Copenhagen.
